Tβ4
Neurotrophic Keratopathy
About ReGenTree
ReGenTree is a private, clinical-stage biotech developing ophthalmic therapies based on the regenerative protein Thymosin β4 (Tβ4). The company is advancing programs for dry eye syndrome and neurotrophic keratopathy, with a Phase 3 trial for the latter indication underway. As part of the broader HLB corporate network, it benefits from shared resources and regional development expertise, particularly in South Korea. The company is currently pre-revenue, with its value hinging on the clinical and regulatory success of its lead Tβ4 candidate.
View full company profileAbout ReGenTree
ReGenTree is a private, clinical-stage biotech developing ophthalmic therapies based on the regenerative protein Thymosin β4 (Tβ4). The company is advancing programs for dry eye syndrome and neurotrophic keratopathy, with a Phase 3 trial for the latter indication underway. As part of the broader HLB corporate network, it benefits from shared resources and regional development expertise, particularly in South Korea. The company is currently pre-revenue, with its value hinging on the clinical and regulatory success of its lead Tβ4 candidate.
View full company profileTherapeutic Areas
Other Neurotrophic Keratopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Neurotrophic Keratopathy Studies | Oculus Research | Not Applicable (Service Provider) |